Lu-177 vipivotide tetraxetan shifted from post-taxane mCRPC to pre-chemotherapy mCRPC and then metastatic hormone-sensitive ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
This was corrected on Aug. 3, 2026. Novartis' Pluvicto was approved for use in combination with an androgen receptor pathway inhibitor. The original version incorrectly said androgen deprivation ...
- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists ...
Novartis got a clinical data boost that could support its radiotherapy Pluvicto’s $2 billion-plus peak sales ambition. Pluvicto helped patients with previously treated PSMA-positive metastatic ...
Morning Overview on MSN
The FDA expanded a radioactive prostate-cancer drug to more men earlier
Federal regulators have broadened the approved use of a radioactive prostate-cancer therapy so that many more men can receive it, and receive it earlier in the course of their disease. The move ...
Novartis has high hopes for its radiotherapy Pluvicto. But as the Swiss pharma aims to move the drug into an earlier treatment setting in prostate cancer, it has posted a mixed bag of trial data that ...
Novartis (NYSE:NVS) said on Monday that its radioligand therapy Pluvicto (INN: lutetium 177Lu) met the main goal of a phase 3 trial in certain patients with prostate cancer. The study, dubbed PSMAfore ...
The administration of Pluvicto within six months of radium-223 treatment proved to be safe and efficacious in patients with metastatic castration-resistant prostate cancer, research showed. Patients ...
What Is Pluvicto and How Does It Work? The FDA has approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat adults with a specific type of advanced prostate cancer. It is used for prostate ...
The market for radioligand therapies (RLT), also known as radiopharmaceuticals, a relatively new kind of treatment, is expected to soar between now and 2030, with Novartis' (NYSE:NVS) Pluvicto ...
Everyday Health on MSN
Navigating radioligand therapy infusion days and at-home radiation safety for prostate cancer
Learn what to expect during radioligand therapy infusion for prostate cancer, including safety protocols, side effects, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results